Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 24, Issue 5, 2007, Pages 445-492

  Xu, Fuguo ^a   Ma, Qingyong ^a   Sha, Huanchen ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Antiangiogenesis; Antitumor; Combination therapy; Gene delivery; Targeted therapy; Vascular targeting agent

Indexed keywords

ADENOVIRUS VECTOR; ADRENOMEDULLIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; COLLAGEN; CYCLOPHOSPHAMIDE; CYTOSINE DEAMINASE; DOXORUBICIN; ENDOSTAR; ENDOSTATIN; FIBROBLAST GROWTH FACTOR 2; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN G3; LENTIVIRUS VECTOR; NAVELBINE; PARVOVIRUS VECTOR; PROTEIN KINASE C ALPHA; PROTEIN P53; RECOMBINANT ENDOSTATIN; RESISTIN; RETROVIRUS VECTOR; SEMAXANIB; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VASOACTIVE INTESTINAL POLYPEPTIDE; YH 16;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC GENE THERAPY; ATRIOVENTRICULAR BLOCK; BIOLOGICAL THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG APPROVAL; DRUG HALF LIFE; DRUG SYNTHESIS; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; INJECTION SITE REACTION; LOW DRUG DOSE; NANOTECHNOLOGY; NEOPLASM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OSMOTIC MINIPUMP; PRURITUS; QUALITY OF LIFE; RASH; REVIEW; SINUS TACHYCARDIA; SKIN ALLERGY; SUICIDE GENE THERAPY; SUPRAVENTRICULAR PREMATURE BEAT; THORAX PAIN; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM;

EID: 38049036452     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v24.i5.20     Document Type: Review

References (165)

1. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol. 2002;20:3906-27.
2. Emmenegger U, Kerbel RS. A dynamic de-escalating dosing strategy to determine the optimal biological dose for antiangiogenic drugs. Clin Cancer Res. 2005;11:7589-92.
3. Herbst RS, Lee AT, Tran HT, Abbruzzese JL. Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin. Curr Oncol Rep. 2001;3:131-40.
4. Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res. 2006;66:11520-39.
5. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671-4.
6. Folkman J. Endogenous angiogenesis inhibitors. APMIS. 2004;112:496-507.
7. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-57.
8. Yang W, Li XY. Anti-tumor effect of pEgr-interferon-gamma-endostatin gene-radiotherapy in mice bearing Lewis lung carcinoma and its mechanism. Chin Med J (Engl). 2005;118:296-301.
9. Daly ME, Makris A, Reed M, Lewis CE. Hemostatic regulators of tumor angiogenesis: a source of antiangiogenic agents for cancer treatment? J Natl Cancer Inst. 2003;95:1660-73.
10. Cui R, Ohashi R, Takahashi F, Yoshioka M, Tominaga S, Sasaki S, Gut T, Takagi Y, Takahashi K. Signal transduction mediated by endostatin directly modulates cellular function of lung cancer cells in vitro. Cancer Sci. 2007;6:1349-57.
11. Du Z, Hou S. The anti-angiogenetic activity of human endostatin inhibits bladder cancer growth and its mechanism. J Urol. 2003;170:2000-3.
12. Ye CS, Feng C, Wang SM, Liu XN, Lin YJ, Li MF. Antiangiogenic and antitumor effects of endostatin on follicular thyroid carcinoma. Endocrinology. 2002;143:3522-8.
13. Liang ZH, Wu PH, Li L, Xue G, Zeng YX, Huang WL. Inhibition of tumor growth in xenografted nude mice with adenovirus-mediated endostatin gene comparison with recombinant endostatin protein. Chin Med J (Engl). 2004;117:1809-14.
14. Ryan DP, Penson RT, Ahmed S, Chabner BA, Lynch TJ Jr. Reality testing in cancer treatment: the phase I trial of endostatin. Oncologist. 1999;4:501-8.
15. Kulke MH, Bergsland EK, Ryan DP, Enzinger DC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol. 2006;24:3555-61.
16. Herbst RS. Targeted therapy using novel agents in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2002;3:S30-8.
17. Chang Z, Choon A, Friedl A. Endostatin binds to blood vessels in situ independent of heparan sulfate and does not compete for fibroblast growth factor-2 binding. Am J Pathol. 1999;155:71-6.
18. Yang F, He YL. Recombinant human endostatin induces apoptosis of human umbilical venous endothelial cells. Nan Fang YE Ke Da Xue Xue Bao. 2006;26:978-80.
19. Miyoshi T, Hirohata S, Ogawa H, Doi M, Obika M, Yonezawa T, Sado Y, Kusachi S, Kyo S, Kondo S, Shiratori Y, Hudson BG, Ninomiya Y. Tumor-specific expression of the RGD-03 (IV) NCI domain suppresses endostatin tube formation and tumor growth in mice. FASEB J. 2006;20:1904-6.
20. Le QT, Giaccia AJ. Therapeutic exploitation of the physiological and molecular genetic alterations in head and neck cancer. Clin Cancer Res. 2003;9:4287-95.
21. Moschos SJ, Odoux C, Land SR, Agarwala S, Friedland D, Volker KM, Sidor C, Wong M, Kirkwood JM. Endostatin plus interferon-alpha 2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents. Melanoma Res. 2007;17:193-200.
22. Sánchez-Arévalo Lobo VJ, Cuesta AM, Sanz L, Compte M, Carcía P, Prieto J, Blanco FJ, Alvarez-Vallina L. Enhanced antiangiogenic therapy with antibody-collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events. Int J Cancer. 2006;119:455-62.
23. Ribatti D, Conconi MT, Nussdorfer GG. Nonclassic endogenous novel regulators of angiogenesis. Pharmacol Rev. 2007;59:185-205.
24. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-6.
25. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Inst. 1990;82:4-6.
26. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular disease, and chronic inflammation. Pharmacol Rev. 2000;52:237-68.
27. Li CY, Shan S, Huang Q, Braun RD, Lanzen J, Hu K, Lin P, Dewhirst MW. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst. 2000;92:143-7.
28. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Angustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implication for antiangiogenic tumor therapies. Cancer Res. 2000;60:1388-93.
29. Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M, Hossfeld DK. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood .1997;89:1870-5.
30. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-64.
31. Pestell RG, Li ZP. Antisense to cyclin D1 inhibits VEGF-stimulated growth of vascular endothelial cells: implication of tumor vascularization. Clin Cancer Res. 2006;12:4459-62.
32. Persano L, Crescenzi M, Indraccolo S. Anti-angiogenic gene therapy of cancer: current status and future prospects. Mol Aspects Med. 2007;28:87-114.
33. Sund M, Hamano Y, Sugimoto H, Sudhakar A, Soubasakos M, Yerramalla U, Benjamin LE, Lawler J, Kieran M, Shah A, Kalluri R. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci U S A. 2005;102:2934-9.
34. Gong YQ, Agani FH. Oligomycin inhibits HIF-1a expression in hypoxic tumor cells. Am J Physiol Cell Physiol. 2005;288:c1023-9.
35. Kang HJ, Kim HJ, Rih JK, Mattson TL, Kim KW, Cho CH, Rosen EM, Bael L. BRCA1 plays a role in the hypoxic response by regulating HIF-1a stability and by modulating vascular endothelial growth factor expression. J Biol Chem. 2006; 281:13047-56.
36. Bernardi R, Guernah L, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J, Cordon-Cardo C, Simon MC, Rafli S, Pandolfi PP. PML inhibits HIF-1a translation and neoangiogensis through repression of mTOR. Nature. 2006;442:779-85.
37. Chen WT, Huang CJ, Wu MT, Yang SF, Su YC, Chai CY. Hypoxia-inducible factor-10 is associated with risk of aggressive behavior and tumor angiogenesis in gastrointestinal stromal tumor. Jpn J Clin Oncol. 2005;35:207-13.
38. Yogendra S. Tumor angiogenesis: clinical implications. Nepal J Neurosci. 2004;1:61-3.
39. Brock CS, Lee SM. Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer. Eur Respir J. 2002;19:557-70.
40. Nyberg P, Xie L, Kalluri K. Endogenous inhibitors of angiogenesis. Cancer Res. 2005;65:3967-79.
41. Lefesvre P, Attema J, van Bekkum D. Adenoviral gene transfer of angiostatic ATF-BPTI inhibits tumor growth. BMC Cancer. 2002;2:17-26.
42. Boehm T, Folkman J, Brouder T, Browder T, O'Reilly. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390:404-7.
43. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-85.
44. Heljasvaara R, Nvberq P, Luostarinen J, Parikka M, Heikkilav P, Rehn M, Sorsa T, Salo T, Pihlajaniemi T. Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. Exp Cell Res. 2005;307:292-304.
45. Yokoyama Y, Ramakrishnan S. Addition of an aminopeptidase N-binding sequence to human endostatin improves inhibition of ovarian carcinoma growth. Cancer. 2005;104:321-31.
46. Kranenburg O, Kroon-Batenburg LM, Reijerker A, Wu YP, Voest EE, Gebbink MF. Recombinant endostatin forms amyloid fibrils that bind and are cytotoxic to murine neuroblastoma cells in vitro. FEBS Lett. 2003;539:149-55.
47. Marneros AG, Olsen BR. Physiological role of collagen XVIII and endostatin. FASEB J. 2005;19:716-28.
48. Wickström SA, Alitalo K, Keski-Oja J. Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res. 2002;62:5580-9.
49. Whitworth A. Endostatin: are we waiting for Godot? J Natl Cancer Inst. 2006;98:731-3.
50. Iozzo RV, San Antonio JD. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest. 2001;108:349-55.
51. Delaney CE, Weagant BT, Addision C. The inhibitory effects of endostatin on endothelial cells are modulated by extracellular matrix. Exp Cell Res. 2006;312:2476-89.
52. Clamp A, Blackhall FH, Henrioud A, Jayson GC, Javaherian K, Esko J, Gallagher JT, Merry CL. The morphogenic properties of oligomeric endostatin are dependent on cell surface heparin sulfate. J Biol Chem. 2006;281:14813-22.
53. Dixelius J, Olsson AK, Thulin Å, Lee C, Johansson I, Claesson-Welsh L. Minimal active domain and mechanism of action of the angiogenesis inhibitor histidinerich glycoprotein. Cancer Res. 2006;66:2089-97.
54. Mehta D, Malik AB. Signaling mechanisms regulating endothelial permeability. Physiol Rev. 2006;86:279-367.
55. Bix G, Castello R, Burrows M, Zoeller JJ, Weech M, Iozzo RA, Cardic C, Thakur ML, Barker CA, Camphausen K, Iozzo RV. Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. J Natl Cancer Inst. 2006;98:1634-46.
56. Jia HP, Kling J. China offers alternative gateway for experimental drugs. Nat Biotechnol. 2006;24:117-8.
57. van Hinsbergh VWM, Engelse MA, Quax PHA. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol. 2006;26:716-28.
58. Skovseth DK, Veuger MJ, Sorensen DR, De Angelis PM, Haraldsen G. Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood. 2005;105:1044-51.
59. Wenzel D, Schmidt A, Reimann K, Hescheler J, Pfitzer G, Bloch W, Fleischmann BK. Endostatin, the proteolytic fragment of collagen XVIII, induces vasorelaxation. Circ Res. 2006;98:1203-99.
60. Davis DW, Shen Y, Mullani NA, Wen SJ, Herbst RS, O'Reilly M, Abbruzzese JL, McConkey DJ. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary tumors. Clin Cancer Res. 2004;10:33-42.
61. Janér J, Andersson S, Haglund C, Lassus P. Pulmonary endostatin perinatally and in lung injury of the newborn infant. Pediatrics. 2007;119:e241-6.
62. Singhal S, Vachani A, Danielle AO, Kaiser L, Albelda SM. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res. 2005;11:3974-86.
63. Digtyar AV, Pozdnyakova NV, Feldman NB, Lutsenko SV, Severin SE. Endostatin: current concepts about its biological role and mechanisms of action. Biochemistry (Mosc). 2007;72:235-46.
64. Hanai J, Gloy J, Karumanchi SA, Kale S, Tang J, Hu G, Chan B, Ramchandran R, Jha V, Sukhatme VP, Sokol S. Endostatin is a potential inhibitor of Wnt signaling. J Cell Biol. 2002;158:529-39.
65. Tjin Tham Sjin RM, Satchi-Fainaro R, Birsner AE, Ramanujam VMS, Folkman J, Javaherian K. A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res. 2005;65:3656-63.
66. Woo IS, Kim KA, Jeon HM, Hong SH, Rho SY, Koh SJ, Lee MA, Byun JH, Kang JH, Hong YS, Lee KS, Cho CS, Choi MG, Chung IS. Pretreatment serum endostatin as a prognostic indictor in metastatic gastric carcinoma. Int J Cancer. 2006;119:2901-6.
67. Feldman AL, Tamarkin L, Paciotti GF, Simpson BW, Linehan WM, Yang JC, Fogler WE, Tuner EM, Alexander HR Jr, Libutti SK. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res. 2000;6:4628-34.
68. Schips L, Dalpiaz O, Lipsky K, Langer C, Rehak P, Puerstner P, Pummer K, Zigeuner R. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur Urol. 2007;51:168-74.
69. Dhanabal M, Ramchandran R, Volk R, Stillman IE, Lombardo M, Iruela-Arispe ML, Simons M, Sukhatme VP. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res. 1999;59:189-97.
70. Wu J, Fu W, Luo J, Zhang T. Expression and purification of human endostatin from Hansenula polymorpha A16. Protein Expr Purif. 2005;42:12-9.
71. Zhang HY, Han QW, Xu YF, Fan YR, Dai QM, Xu JM, Zhu HW, Rong ZG, Wang JJ, Xu GX. The methods for determining the purity and in vitro or in vivo activity of recombinant human endostatin. Cancer Biol Ther. 2005;4:207-12.
72. Xu HM, Zhang GY, Ji XD, Cao L, Shu L, Hua ZC. Expression of soluble, biologically active recombinant human endostatin in Escherichia coli. Protein Expr Purif. 2005;41:252-8.
73. Su Z, Wu X. Feng Y, Ding C, Xiao Y, Cai L, Feng W Li X. High level expression of human endostatin in Pichia pastoris using a synthetic gene construct. Appl Microbiol Biotechnol.2007;73:1355-62.
74. Huang X, Wong MK, Zhao Q, Zhu Z, Wang KZ, Huang N, Ye C, Gorelik E, Li M. Soluble recombinant endostatin purified from Escherichia coli: antiangiogenic activity and antitumor effect. Cancer Res. 2001;61:478-81.
75. Ling Y, Yang Y, Lu N, You QD, Wang S, Gao Y, Chen Y, Guo QL. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun. 2007;361:79-84.
76. Li XP, Li CY, Li X, Ding Y, Chan LL, Yang PH, Li G, Liu X, Lin JS, Wang J, He M, Kung HF, Lin MC, Peng Y. Inhibition of human nasopharyngeal carcinoma growth and metastasis in mice by adenovirus-associated virus-mediated expression of human endostatin. Mol Cancer Ther. 2006;5:1290-8.
77. Stout JT. Gene transfer for the treatment of neovascular ocular disease [an American Ophalmological Society thesis]. Trans Am Ophthalmol Soc. 2006;104:530-60.
78. Xu YF, Zhu LP, Hu B, Fu GF, Zhang HY, Wang JJ, Xu GX. A new expression plasmid in Bifidobacterium longum as a delivery system of endostatin for cancer gene therapy. Cancer Gene Ther. 2007;14:151-7.
79. Scappaticci FA, Contreras A, Smith R, Bonhoure L, Lum B, Cao Y, Engleman EG, Nolan GP. Statin-AE: a novel angiostatin-endostatin fusion protein with enhanced antiangiogenic and antitumor activity. Angiogenesis. 2001;4:263-8.
80. Zheng AQ, Song XR, Yu JM, Wang XW. Liposome transfected to plasmid-encoding endostatin gene combined with radiotherapy inhibits liver cancer growth in nude mice. World J Gastroenterol. 2005;11:4439-42.
81. Li X, Fu GF, Fan YR, Shi CF, Liu XJ, Xu GX, Wang JJ. Potent inhibition of angiogenesis and liver tumor growth by administration of an aerosol containing a transferrin-liposome-endostatin complex. World J Gastroenterol. 2003;9:262-6.
82. Wei ZT, Wang XY, Dong JC, Ma CH, Zhao D, Zhang Y, Sun WS. Inhibitory effect of endostatin mediated by lipofectin on transplanted ovarian cancer. Zhonghua Fu Chan Ke Za Zhi. 2005;40:396-9.
83. Simberg D, Weisman S, Talmon Y, Barenholz Y. DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. Crit Rev Ther Drug Carrier Syst. 2004;21:257-317.
84. Kim KS, Kim HS, Park JS, Kwon YG, Park YS. Inhibition of B16BL6 tumor progression by coadministration of recombinant angiostatin K1-3 and endostatin genes with cationic liposomes. Cancer Gene Ther. 2004;11:441-9.
85. Yuan AQ, He YL, Yang F, Liu MB. Construction of a recombinant adenoviral vector expressing human endostatin. Nan Fang Yi Ke Da Xue Xue Bao. 2006;26:1769-71.
86. Sun J, Wang JQ, Zhang ZY. Two incompatible plasmids coexpress the human endostatin and predigested human plasminogen kringle 5 in E. coli. Sichuan Da Xue Xue Bao Yi Xue Ban. 2006;37:839-43.
87. Liu YZ, Deisseroth A. Tumor vascular targeting therapy with viral vectors. Blood. 2006;107:3027-33.
88. Wang X, Liu F, Li X, Li J, Xu G. Anti-tumor effect of human endostatin mediated by retroviral gene transfer in nude mice. Chin Med J (Engl). 2002;115:1664-9.
89. Kikuchi E, Menendez S, Ohori M, Cordon-Cardo C, Kasahara N, Bochner BH. Inhibition of orthotopic human bladder tumor growth by lentiviral gene transfer of endostatin. Clin Cancer Res. 2004;10:1835-42.
90. Huang BJ, Liu RY, Huang JL, Liang ZH, Gao GF, Wu JX, Huang W. Long-term toxicity studies in canine of E10A, an adenoviral vector for human endostatin gene. Hum Gene Ther. 2007;18:207-21.
91. Wen XY, Bai Y, Stewart AK. Adenovirus-mediated human endostatin gene delivery demonstrates strain-specific antitumor activity and acute dose-dependent toxicity in mice. Hum Gene Ther. 2001;12:347-58.
92. Liu H, Peng CH, Liu YB, Wu YL, Zhao ZM, Wang Y, Han BS. Inhibitory effect of adeno-associated virus-mediated gene transfer of human endostatin on hepatocellular carcinoma. World J Gastroenterol. 2005;11:3331-4.
93. Chen CT, Lin J, Li Q, Phipps SS, Jakubczak JL, Stewart DA, Skripchenko Y, Forry-Schaudies S, Wood J, Schnell C, Hallenbeck PL. Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin. Hum Gene Ther. 2000;11:1983-96.
94. Pulkkanen KJ, Laukkannen JM, Fuxe J, Kettunen MZ, Rehn M, Kannasto JM, Parkkinen JJ, Kauppinen RA, Pettersson RF, Yla-Herttuala S. The combination of HSV-tk and endostatin gene therapy eradicates orthotopic human renal cell carcinomas in nude mice. Cancer Gene Ther. 2002;9:908-16.
95. Shi W, Teschendorf C, Muzyzczka Z, Siemann DW. Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Ther. 2002;9:513-21.
96. Lu BX, Han RF, Tang Y, Han YZ, Li SZ. Gene therapy of bladder cancer by using recombinant adeno-associated virus-endostatin: experiments in vitro and in vivo. Zhonghua Yi Xue Za Zhi. 2007;87:802-5.
97. Zhang XF, Xu JF, Lawler J, Terwilliger E, Parangi S. Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin. Clin Cancer Res. 2007;13:3968-76.
98. Ponnazhagan S, Mahendra G, Kumar S, Shaw DR, Stockard CR, Grizzle WE, Meleth S. Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res. 2004;64:1781-7.
99. te Velde EA, Reijerkerk A, Brandsma D, Vogten JM, Wu Y, Kranenburg O, Voest EE, Gebbink M, Borel Rinkes IH. Early endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells. Br J Cancer. 2005;92:729-35.
100. Cho H, Kim WJ, Lee YM, Kim YM, Kwon YG, Park YS, Choi EY, Kim KN. N-/Cterminal deleted mutant of human endostatin efficiently acts as an anti-angiogenic and anti-tumorigenic agent. Oncol Rep. 2004;11:191-5.
101. Kirsch M, Weigel P, Pinzer T, Carroll RS, Black PM, Schacket HK, Schachert G. Therapy of hematogenous melanoma brain metastases with endostatin. Clin Cancer Res. 2005;11:1259-67.
102. Becker CM, Wright RD, Satchi-Fainaro R, Funakoshi T, Folkman J, Kung AL, D'Amato RJ. A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy. Am J Pathol. 2006;168:2074-84.
103. Folkman J. Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res. 2005;312:594-607.
104. Sim BK, Fogler WE, Zhou XH, Liang H, Madsen JW, Luu K, O'Reilly MS, Tomaszewski JE, Fortier AH. Zinc ligand-disrupted recombinant human endostatin: potent inhibitor of tumor growth, safety and pharmacokinetic profile. Angiogenesis. 1999;3:41-51.
105. Xu YF, Zhu LP, Hu B, Rong ZG, Zhu HW, Xu JM,Wu ZW, Wang JJ, Xu GX. A quantitative method for measuring the antitumor potency of recombinant human endostatin in vivo. Eur J Pharmacol. 2007;564:1-6.
106. Ding I, Sun JZ, Fenton B, Liu WM, Kimsely P, Okunieff P, Min W. Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas. Cancer Res. 2001;61:526-31.
107. Song HF, Liu XW, Zhang HN, Zhu BZ, Yuan SJ, Liu SY, Tang ZM. Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys. Acta Pharmacologica Sinica. 2005;26:124-8.
108. Yang XX, Hu ZP, Chan E, Duan W, Zhou S. Pharmacokinetics of recombinant human endostatin in rats. Curr Drug Metab. 2006;7:565-76.
109. Schmidt NO, Ziu M, Carrabba G, Giussani C, Bello L, Sun YP, Schmidt K, Albert M, Black PM, Carroll RS. Antiangiogenic therapy by local intracerebral microinfusion improves treatment efficiency and survival in an orthotopic human glioblastoma model. Clin Cancer Res. 2004;10:1255-62.
110. Kuroiwa M, Takeuchi T, Lee JH, Yoshizawa J, Hirato J, Kaneko S, Choi SH, Suzuki N, Ikeda H, Tsuchida Y. Continuous versus intermittent administration of human endostatin in xenografted human neuroblastoma. J Pediatr Surg. 2003;38:1499-505.
111. Kisker O, Becker CM, Prox D, Fannon M, D'Amato RD, Flynn E, Fogler WE, Sim BK, Allred EN, Pirie-Shepherd SR, Folkman J. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 2001;61:7669-74.
112. Barnett FH, Scharer-Schuksz M, Wood M, Yu X, Wagner TE, Friedlander M. Intra-arterial delivery of endostatin gene to brain tumors prolongs survival and alters tumor vessel ultrastructure. Gene Ther. 2004;11:1283-9.
113. Read TA, Farhadi M, Bjerkvig R, Olsen BR, Rokstad AM, Huszthy PC, Vajkoczy P. Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cells. Cancer Res. 2001;61:6830-7.
114. Yokoyama Y, Ramakrishnan S. Addition of integrin-binding sequence to a mutant human endostatin improves inhibition of tumor growth. Int J Cancer. 2004;111:839-48.
115. Zhang Y, Wang W, Zhou J, Yu W, Zhang X , Guo X ,Ma X. Tumor anti-angiogenic gene therapy with microencapsulated recombinant CHO cells. Ann Biomed Eng. 2007;35:605-14.
116. Verma RK, Arora S, Garg S. Osmotic pumps in drug delivery. Crit Rev Ther Drug Carrier Syst. 2004;21:477-520.
117. Berger A. Drug system may combat cancer. BMJ. 2001;322:72.
118. Teng HN, Zhang Y, Wang W, Ma XJ, Fei J. Inhibition of tumor growth in mice by endostatin derived from abdominal transplanted encapsulated cells. Acta Biochim Biophys Sin. 2007;39:278-84.
119. Joki T, Machluf M, Atala A, Zhu J, Sevfried NT, Dunn IF, Abe T, Carroll RS, Black PM. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol. 2001;19:35-9.
120. Sinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther. 2006;5:1909-17.
121. Nahar M, Dutta T, Murugesan S, Asthana A, Mishra D, Rajkumar V, Tare M, Saraf S, Jain NK. Functional polymeric nanoparticles: an efficient and promising tool for active delivery of bioactives. Crit Rev Ther Drug Carrier Syst. 2006;23:259-318.
122. Mustata G, Dinh SM. Approches to oral drug delivery for challenging moleculars. Crit Rev Ther Drug Carrier Syst. 2006;23:111-35.
123. Hansma AH, Broxterman HJ, van der Horst I, Yuana Y, Boven E, Giaccone G, Pinedo HM, Hoekman K. Recombinant human endostatin administered as a 28-day continuous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. Ann Oncol. 2005;16:1695-701.
124. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, Pluda J, Hong WK, Abbruzzese JL. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2002;20:3792-803.
125. Eder JP Jr, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe DW. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol. 2002;20:3772-84.
126. Yang L, Wang JW, Sun Y, Zhu YZ, Liu XQ, Li WL, Di LJ, Li PW, Wang YL, Song SP, Yao C, You LF. Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer. Chin J Oncol. 2006;28:138-41.
127. Bachelot T, Ratel D, Menetrier-Caux C, Wion D, Blay JY, Berger F. Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome. Br J Cancer. 2006;10;94:1066-70.
128. Mundhenke C, Thomas JP, Wilding G, Lee FT, Kelzc F, Chappell R, Neider R, Sebree LA, Friedl A. Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin Cancer Res. 2001;7:3366-74.
129. Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, Tutsch K, Geiger P, Pluda J, Fogler W, Schiller JH, Wilding G. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2003;21:223-31.
130. Cao Y, Li S, Li HL, Li YH, Zhang DS, Guo Y, Li XL, Lin XB, Huang WL, Jiang WQ. Clinical tolerance trial on recombinant human endostatin adenovirus. Ai Zheng. 2007;26:856-60.
131. Wang JW, Sun Y, Liu YY, Yu QT, Zhang YP, Li K, Zhu YZ, Zhou QH, Hou M, Guan ZZ, Li WL, Zhuang W, Wang DL, Liang HJ, Qin FZ, Lu HS, Liu XQ, Sun H, Zhang YJ, Wang JJ, Luo SX, Yang RH, Tu YR, Wang XW, Song SP, Zhou JM, You LF, Wang J, Yao C. Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer. 2005;8:283-90.
132. Shi W, Teschendorf C, Muzyzczka Z, Siemann DW. Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother Oncol. 2003;66:1-9.
133. Hanna NN, Seetharam S, Mauceri HJ, Beckett MA, Jaskowiak NT, Salloum RM, Hari D, Dhanabal M, Ramchandran R, Kalluri R, Sukhatme VP, Kufe DW, Weichselbaum RR. Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J. 2000;6:287-93.
134. Luo X, Slater JM, Gridley DS. Radiation and endostatin gene therapy in a lung carcinoma model: pilot date on cells and cytokines that affect angiogenesis and immune states. Technol Cancer Res Treat. 2006;5:135-46.
135. Bertolini F, Fusetti L, Mancuso P, Gobbi A, Corsini C, Ferrucci PF, Martinelli G, Pruneri G. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human highgrade non-Hodgkin lymphoma. Blood. 2000;96:282-7.
136. Velde EA, Vogten JM, Gebbink MFGB, van Gorp JM, Voest EE, Borel Rinkes IHM. Enhanced antitumor efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. Br J Surg. 2002;89:1302-9.
137. Plum SM, Hanson AD, Volker KM, Vu HA, Sim BK, Fogler WE, Fortier AH. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model. Clin Cancer Res. 2003;9:4619-26.
138. Kerbel RS. Antiangiogenetic therapy: a universal chemosensitization strategy for cancer? Science. 2006;312:1171-5.
139. Pradilla G, Legnani FG, Petrangolini G, Francescato P, Chillemi F, Tyler BM, Gaini SM, Brem H, Olivi A, DiMeco F. Local delivery of a synthetic endostatin fragment for the treatment of experimental gliomas. Neurosurgery. 2005;57:1032-40.
140. Abraham D, Abri S, Hofmann M, Holtl W, Aharinejad S. Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts. J Urol. 2003;170:1388-93.
141. Wu Y, Yang L, Hu B, Liu JY, Su JM, Luo Y, Ding ZY, Niu T, Li Q, Xie XL, Wen JL, Kan B, Mao YQ, Wei YQ. Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined with gemecitabine. Anticancer Drugs. 2005;16:551-7.
142. Subramanian IV, Bui Nguyen TM, Truskinovsky AM, Tolar J, Blazar BR, Ramakrishnan Sl. Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival. Cancer Res. 2006;66:4319-28.
143. Liu FJ, Tan G, Li J, Dong XS, Krissansen GW, Sun XY. Gene transfer of endostatin enhances the efficacy of doxorubicin to suppress human hepatocellular carcinomas in mice. Cancer Sci. 2007;98:1381-7.
144. Scappaticci FA, Smith R, Pathak A, Schloss D, Lum B, Cao Y, Johnson F, Engleman EG, Nolan GP. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol Ther. 2001;3:186-96.
145. Li X, Raikwar SP, Liu YH, Lee SJ, Zhang YP, Zhang S ,Cheng L, Lee SD, Juliar BE, Gardner TA, Jeng MH, Kao C. Combination therapy of androgen-independent prostate cancer using a prostate restricted replicative adenovirus and a replication-defective adenovirus encoding human endostatin-angiostatin fusion gene. Mol Cancer Ther. 2006;5:676-84.
146. Sacco MG, Cato EM, Ceruti R, Soldati S, Indraccolo S, Caniatti M, Scanziani E, Vezzoni P. Systemic gene therapy with anti-angiogenic factors inhibits spontaneous breast tumor growth and metastasis in MMTVneu transgenic mice. Gene Ther. 2001;8:67-70.
147. Sauter BV, Martinet O, Zhang WJ, Mandeli J, Woo SLC. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci U S A. 2000;97:4802-7.
148. Ohlfest JR, Demorest ZL, Motooka Y, Vengco I, Oh S, Chen E, Scappaticci FA, Scaplis RJ, Ekker SC, Low WC, Freese AB, Largaespada DA. Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. Mol Ther. 2005;12:778-88.
149. Ou-Yang F, Lan KL, Chen CT, Liu JC, Weng CL, Chou CK, Xie X, Hung JY, Wei Y, Hortobagyi GN, Hung MC. Endostatin-cytosine deaminase fusion protein suppresses tumor growth by targeting neovascular endothelial cells. Cancer Res. 2006;66:378-84.
150. Isayeva T, Ren C, Ponnazhagan S. Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway. Gene Ther. 2007;14:138-46.
151. Cho HM, Rosenblatt JD, Kang YS, Iruela-Arispe ML, Morrison SL, Penichet ML, Kwon YG, Kim TW, Webster KA, Nechustan H, Shin SU. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein. Mol Cancer Ther. 2005;4:956-67.
152. Teodoro JG, Parker AE, Zhu XC, Green MR. p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science. 2006;313:968-71.
153. Tai KF, Chen PJ, Chen DS, Hwang LH. Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors. J Gene Med. 2003;5:386-98.
154. Jia LJ, Xu HM, Ma DY, Hu QG, Huang XF, Jiang WH, Li SF, Jia KZ, Huang QL, Hua ZC. Enhanced therapeutic effect by combination of tumor-targeting Salmonella and endostatin in murine melanoma model. Cancer Biol Ther. 2005;4:840-5.
155. Li M, Ye C, Feng C, Riedel F, Liu X, Zeng Q, Grandis JR. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. Clin Cancer Res. 2002;8:3570-8.
156. Abdollahi A, Lipson KE, Sckell A, Zieher H, Klenke F, Poerschke D, Roth A, Han X, Krix M, Bischof M, Hahnfeldt P, Grone HJ, Debus J, Hlatky L, Huber PE. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res. 2003;63:8890-8.
157. Sorensen DR, Leirdal M, Iversen PO, Sioud M. Combination of endostatin and a protein kinase Cá DNA enzyme improves the survival of rats with malignant glioma. Neoplasia. 2002;4:474-9.
158. Quesada AR, Munoz-Chapuli R, Medina MA. Anti-angiogenic drugs: from bench to clinical trials. Med Res Rev. 2006;26:483-530.
159. Mirura M, Sakimoto I, Ohta R, Sugawara F, Sakaguchi K. Sulfoglycolipids as candidate antiangiogenic radiosensitizers. Anti-cancer Drugs. 2007;18:1-5.
160. Wang DY, Anderson JC, Gladson CL. The role of the extracellular matrix in angiogenesis in malignant glioma tumors. Brain Pathol.2005;15:318-26.
161. Mi J, Sarraf-Yazdi S, Zhang XW, Cao Y, Dewhirst MW, Kontos CD, Li CY, Clary BM. A comparison of antiangiogenic therapies for the prevention of liver metastases. J Surg Res. 2006;131:97-104.
162. Régulier E, Paul S, Mariqliano M, Kintz J, Poitevin Y, Ledoux C, Roecklin D, Cauet G, Calenda V, Homann HE. Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach. Cancer Gene Ther. 2001;8:45-54.
163. Martinico SC, Jezzard S, Sturt NJ, Michils G, Tejpar S, Phillips RK, Vassaux G. Assessment of endostatin gene therapy for familial adenomatous polyposis-related desmoid tumors. Cancer Res. 2006;66:8233-40.
164. Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol. 2005;23:1295-311.
165. Ortega N, Werb Z. New functional roles for non-collagenous domains of basement membrane collagens. J Cell Sci. 2002;115:4201-14.